Maria Sharapova loses sponsors; meldonium treatment typically 4-6 weeks, drug company says

MOSCOW — The Latvian company that manufactures meldonium says the normal course of treatment for the drug is four to six weeks — not the 10 years that Russian teis star Maria Sharapova says she used the substance.

The five-time Grand Slam champion said Monday she failed a doping test at the Australian Open in January for meldonium, which became a baed substance under the World Anti-Doping Agency code this year.

The former No. 1 said she had taken meldonium, a heart medicine which improves blood flow and is little-known in the U.S., for a decade following various health problems including regular sicknesses, early signs of diabetes and “irregular” results from echocardiography exams.

“I was first given the substance back in 2006. I had several health issues going on at the time,” she said. Sharapova didn’t specify whether she had used it constantly since then.

Meldonium was baed because it aids oxygen uptake and endurance, and several athletes in various inteational sports have already been caught using it since it was baed on Jan. 1.

Grindeks, which manufactures meldonium, told The Associated Press that four to six weeks was a common course.

“Depending on the patient’s health condition, treatment course of meldonium preparations may vary from four to six weeks. Treatment course can be repeated twice or thrice a year,” the company said in an emailed statement. “Only physicians can follow and evaluate patient’s health condition and state whether the patient should use meldonium for a longer period of time.”

Major sponsors sever ties

Meanwhile, three of Sharapova’s major sponsors cut ties with her in light of her Monday admission.

Sportswear giant Nike, Swiss watch brand Tag Heuer and German luxury car company Porsche moved quickly to distance themselves from Sharapova after she aounced the positive test at a news conference in Los Angeles on Monday.

“We are saddened and surprised by the news about Maria Sharapova,” Nike said in a statement. “We have decided to suspend our relationship with Maria while the investigation continues. We will continue to monitor the situation.”

TAG Heuer said its deal with Sharapova will not be renewed. The sponsorship expired at the end of 2015 and discussions had been taking place on how to extend it.

“In view of the current situation, the Swiss watch brand has suspended negotiations, and has decided not to renew the contract with Ms Sharapova,” TAG Heuer said in a statement.

Porsche said in a statement Tuesday that it has “chosen to postpone plaed activities” with Sharapova “until further details are released and we can analyze the situation.”

Advertisement

Sharapova said she failed a doping test at the Australian Open in January for the little-known drug meldonium, which became a baed substance under the World Anti-Doping Agency code this year. The former world No. 1 took full responsibility for her mistake and could face a lengthy ban from the Inteational Teis Federation, possibly ending her season and preventing her from competing for Russia at the Olympics in Rio de Janeiro.

“I know that with this, I face consequences,” Sharapova said. “I don’t want to end my career this way, and I really hope I will be given another chance to play this game.”

The 28-year-old Sharapova said she has been taking meldonium, a blood flow-promoting drug, for 10 years for numerous health issues. Meldonium was baed because it aids oxygen uptake and endurance, and several athletes across inteational sports have already been caught using it.

Sharapova and all players were notified of the changes in the WADA baed substances list in December. Sharapova claimed she simply missed the change, neglecting to click on the link.

“I take great responsibility and professionalism in my job, and I made a huge mistake,” Sharapova said. “I let my fans down. I let the sport down that I’ve been playing since the age of 4, that I love so deeply.”

Sharapova is one of the top female players of her generation, with 35 career singles titles and over $36 million in career eaings. That eaing potential is thought to be easily dwarfed by the eaings she generates from her commercial appeal.

Sharapova is thought to be the world’s highest-paid female athlete due to endorsement deals and her extensive business ventures, including a high-profile candy line, Sugarpova. Forbes estimated her eaings at $29.5 million for 2015.

What is meldonium?

While Latvian company Grindeks has previously stated that the drug can provide an “improvement of work capacity of healthy people at physical and mental overloads and during rehabilitation period,” the company said Tuesday that it believed the substance would not enhance athletes’ performance in competition and might even do the opposite.

“It would be reasonable to recommend them to use meldonium as a cell protector to avoid heart failure or muscle damage in case of unwanted overload,” the company said.

Grindeks said that, in sports activity, the drug slows down how the body breaks down fatty acids to produce energy.

Grindeks did not comment when asked whether someone with the symptoms Sharapova described would be a suitable patient for meldonium. The company said it was designed for patients with chronic heart and circulation conditions, those recovering from illness or injury and people suffering with “reduced working capacity, physical and psycho-emotional overload.”

Meldonium is not approved by the U.S. Food and Drug Administration.

The AP was able to buy vials and tablets of meldonium over the counter in Moscow on Tuesday. Accompanying documentation stated that side effects could include blood pressure changes, irregular heartbeat and skin conditions.

Testing for meldonium

German anti-doping expert Mario Thevis, who helped to develop the test for meldonium, told the AP that testing was reliable despite meldonium’s recent addition to the WADA baed list.

“As a scientist, you can never say 100 percent, but the substance is non-natural, which means that it can be readily differentiated (from naturally occurring substances),” said Thevis, a professor at the anti-doping laboratory in Cologne, Germany, in a telephone interview. “It can be tested as reliably as any other doping agent.”

He added: “There is a potential of the substance to enhance performance and it has been described as a means to facilitate recovery and to enhance physical as well as mental workload capabilities.”

Thevis said the drug appeared most prevalent in Easte European countries.

“The fact that the substance is available as a prescription drug as well as over the counter in certain formulations, and it is only approved, such a substance, in Easte European, Baltic countries, the probability is that the athlete who is originating from that region has more contact to that sort of substance. It’s a logical consequence,” he said.

Following Sharapova’s drug test failure, Russian Sports Minister Vitaly Mutko said he expected more Russian athletes to test positive for meldonium.

“It’s clear that more upheaval related to this substance awaits us,” he told the Tass agency. “People who do this knew all the responsibility.”

Mutko previously told the R-Sport agency on Monday that meldonium was “of no account” and did not improve athletes’ performance. That followed another doping positive for Russian ice dancer Ekaterina Bobrova, who is a former Olympic gold medalist and European champion.

While meldonium was baed as of Jan. 1, the decision to ban it had been aounced by WADA and sports organizations as early as September 2015. Sharapova said she received an email with information on the changes in December, but did not read the information at the time.

- - , .